<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oncology Product Guide &#187; metastatic colorectal cancer</title>
	<atom:link href="http://www.oncologyproductguide.com/blog/tag/metastatic-colorectal-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.oncologyproductguide.com/blog</link>
	<description>A comprehensive guide to oncology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:00:01 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>ImClone launches ERBITUX® in Canada</title>
		<link>http://www.oncologyproductguide.com/blog/2008/10/31/imclone-launches-erbitux%c2%ae-in-canada/</link>
		<comments>http://www.oncologyproductguide.com/blog/2008/10/31/imclone-launches-erbitux%c2%ae-in-canada/#comments</comments>
		<pubDate>Fri, 31 Oct 2008 06:59:34 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Treatments]]></category>
		<category><![CDATA[ERBITUX®]]></category>
		<category><![CDATA[Health Canada]]></category>
		<category><![CDATA[ImClone Systems Inc.]]></category>
		<category><![CDATA[metastatic colorectal cancer]]></category>

		<guid isPermaLink="false">http://www.oncologyproductguide.com/blog/2008/10/31/imclone-launches-erbitux%c2%ae-in-canada/</guid>
		<description><![CDATA[ImClone Systems Inc. has launched its ERBITUX® (cetuximab) in Canadian market in collaboration with Bristol-Myers Squibb Canada. The product will be commercially available for use in the treatment of metastatic colorectal cancer. It has Health Canada’s approval for use in conjunction with irinotecan in the treatment of cancer patients who are intolerant to irinotecan-based chemotherapy [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.imclone.com/"><img src="http://www.oncologyproductguide.com/blog/wp-content/uploads/2008/10/imclone.png" align="left" height="56" hspace="5" vspace="5" width="200" />ImClone Systems Inc.</a> has launched its ERBITUX® (cetuximab) in Canadian market in collaboration with Bristol-Myers Squibb Canada. The product will be commercially available for use in the treatment of metastatic colorectal cancer. It has Health Canada’s approval for use in conjunction with irinotecan in the treatment of cancer patients who are intolerant to irinotecan-based chemotherapy alone. The trial supporting this approval was conducted by Merck, Germany, ImClone’s partner for ERBITUX outside North America.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.oncologyproductguide.com/blog/2008/10/31/imclone-launches-erbitux%c2%ae-in-canada/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
